Maalox heartburn gastric hyperacidity 40 Chewable Tablets 400mg+ 400mg

Product details
Therapeutic indications
Maalox Chewable Tablets is used in the symptomatic treatment of occasional heartburn and hyperacidity of the stomach.

Dosage and method of use
Maalox Chewable Tablets should be taken in the following doses and methods: 1-2 tablets 4 times a day well chewed or sucked, 20-60 minutes after meals and before bedtime. Their intake can be followed by the ingestion of water or milk. Pediatric administration of the drug is not recommended.

Do not exceed the maximum indicated dose.

Contraindications

Hypersensitivity to the active substances or to any of the excipients.
Contraindicated in patients with porphyria.
Severe forms of renal failure
Generally contraindicated in pediatric age.
State of cachexia.
Special warnings
Aluminum hydroxide can cause constipation and an overdose of magnesium salts can cause hypomotility of the intestine; high doses of this medicine may cause or aggravate intestinal obstruction and ileus in patients at higher risk, such as those with renal impairment, with underlying constipation, with impaired bowel motility, in children (0 to 24 months) , or elderly.

Aluminum hydroxide is not well absorbed from the gastrointestinal tract, and systemic effects are therefore rare in patients with normal renal function. However, excessive doses or long-term use, or even normal doses in patients with low phosphorus diets or children (0 to 24 months), can lead to phosphate elimination (due to an aluminum-phosphate bond) accompanied by an increase in bone resorption and hypercalciuria with risk of osteomalacia. It is advisable to consult your doctor in case of long-term use or in patients at risk of hypophosphataemia.

In patients with renal impairment, plasma levels of aluminum and magnesium tend to increase causing hyperalluminaemia and hypermagnesaemia, respectively. In these patients, long exposures to high doses of aluminum and magnesium salts can lead to encephalopathies, dementia, microcytic anemia or worsening of dialysis osteomalacia. Aluminum hydroxide may not be safe in patients with porphyria undergoing hemodialysis.

In the presence of severe forms of renal insufficiency it is recommended to take the product under the direct supervision of a doctor. Prolonged use of the medicinal product should be avoided in these patients. MAALOX tablets contain sucrose: this should be taken into account in case of diabetes or low-calorie diets. Due to the presence of sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose isomaltase deficiency should not take MAALOX chewable tablets. Maalox Chewable Tablets contains parahydroxybenzoates (methyl and propyl parahydroxybenzoate) which can cause allergic reactions (possibly delayed type).

Due to the presence of sorbitol both in the oral suspension and in the tablets, patients with rare hereditary problems of fructose intolerance should not take MAALOX.

Pregnancy and breastfeeding

Pregnancy
The medicine should only be used when needed, under the direct supervision of the doctor, after evaluating the expected benefit to the mother in relation to the possible risk to the fetus or infant.

Feeding time
Due to limited maternal absorption when taken according to the indicated dosage regimen, aluminum hydroxide and its combinations with magnesium salts are considered compatible with breastfeeding.

Expiration and retention
Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored. Store at a temperature not lower than + 4 ° C. Keep the bottle tightly closed.

Warning: do not use the medicine after the expiry date indicated on the package.

Composition
Maalox Chewable Tablets contains:
Active ingredient: magnesium hydroxide 400 mg, aluminum oxide hydrate 400 mg
Excipients: Sucrose powder with starch, sorbitol, mannitol, magnesium stearate, mint flavoring powder, sodium saccharin, sucrose

This sheet has been prepared using information provided by the manufacturer. It should be noted that the packaging of the products is susceptible to periodic renewals by the pharmaceutical companies, therefore the photo of the product may not be updated